Benjamin F. Edwards & Company Inc. Takes $80,000 Position in Lantheus Holdings, Inc. (NASDAQ:LNTH)

Benjamin F. Edwards & Company Inc. acquired a new stake in Lantheus Holdings, Inc. (NASDAQ:LNTH) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund acquired 998 shares of the medical equipment provider’s stock, valued at approximately $80,000.

Several other institutional investors also recently bought and sold shares of the company. Vanguard Group Inc. increased its stake in Lantheus by 5.6% in the 1st quarter. Vanguard Group Inc. now owns 7,362,969 shares of the medical equipment provider’s stock valued at $458,271,000 after buying an additional 389,828 shares during the period. Westfield Capital Management Co. LP increased its stake in Lantheus by 25.3% in the 1st quarter. Westfield Capital Management Co. LP now owns 1,958,018 shares of the medical equipment provider’s stock valued at $121,867,000 after buying an additional 394,837 shares during the period. Farallon Capital Management LLC increased its stake in Lantheus by 595.3% in the 1st quarter. Farallon Capital Management LLC now owns 1,483,227 shares of the medical equipment provider’s stock valued at $92,316,000 after buying an additional 1,269,900 shares during the period. Reinhart Partners LLC. grew its stake in shares of Lantheus by 8.4% during the 1st quarter. Reinhart Partners LLC. now owns 1,470,383 shares of the medical equipment provider’s stock worth $91,517,000 after purchasing an additional 114,110 shares during the period. Finally, Dimensional Fund Advisors LP grew its stake in shares of Lantheus by 1.6% during the 2nd quarter. Dimensional Fund Advisors LP now owns 1,239,502 shares of the medical equipment provider’s stock worth $99,525,000 after purchasing an additional 19,071 shares during the period. 99.06% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

LNTH has been the topic of a number of recent analyst reports. JMP Securities lowered their price target on shares of Lantheus from $130.00 to $125.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 1st. Redburn Atlantic initiated coverage on shares of Lantheus in a research note on Tuesday, September 3rd. They set a “buy” rating and a $175.00 price target on the stock. B. Riley upped their price target on shares of Lantheus from $105.00 to $146.00 and gave the stock a “buy” rating in a research note on Thursday, July 25th. Truist Financial lowered their price target on shares of Lantheus from $141.00 to $135.00 and set a “buy” rating on the stock in a research note on Thursday, August 1st. Finally, Leerink Partners boosted their price objective on shares of Lantheus from $106.00 to $127.00 and gave the stock an “outperform” rating in a research report on Thursday, July 11th. Two equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus price target of $126.00.

Insider Buying and Selling at Lantheus

In other news, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, July 15th. The shares were sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now directly owns 62,216 shares in the company, valued at approximately $7,661,900.40. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. In other news, Director Gerard Ber sold 15,500 shares of the stock in a transaction dated Monday, August 12th. The shares were sold at an average price of $96.48, for a total transaction of $1,495,440.00. Following the transaction, the director now directly owns 21,221 shares in the company, valued at approximately $2,047,402.08. The sale was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, CAO Andrea Sabens sold 341 shares of the stock in a transaction dated Monday, July 15th. The stock was sold at an average price of $123.15, for a total transaction of $41,994.15. Following the transaction, the chief accounting officer now owns 62,216 shares in the company, valued at $7,661,900.40. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 40,852 shares of company stock worth $3,922,001. Corporate insiders own 1.50% of the company’s stock.

Lantheus Price Performance

NASDAQ:LNTH opened at $107.36 on Friday. The firm has a market cap of $7.44 billion, a price-to-earnings ratio of 16.39 and a beta of 0.50. The company has a current ratio of 4.68, a quick ratio of 4.41 and a debt-to-equity ratio of 0.55. The company’s 50-day moving average is $104.45 and its two-hundred day moving average is $85.69. Lantheus Holdings, Inc. has a 12-month low of $50.20 and a 12-month high of $126.89.

Lantheus (NASDAQ:LNTH) last released its earnings results on Wednesday, July 31st. The medical equipment provider reported $1.61 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.68 by ($0.07). The firm had revenue of $394.10 million during the quarter, compared to analysts’ expectations of $382.12 million. Lantheus had a net margin of 29.80% and a return on equity of 48.36%. Lantheus’s revenue for the quarter was up 22.5% on a year-over-year basis. During the same quarter last year, the company posted $1.40 earnings per share. Research analysts expect that Lantheus Holdings, Inc. will post 5.99 EPS for the current year.

Lantheus Company Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.